NicOx enrolls osteoarthritis Phase III

NicOx (Euronext:Nicox) completed enrollment of 820 patients in a double-blind, placebo- and naproxen-controlled U.S. Phase III trial of HCT 3012 to treat osteoarthritis of the knee. The co-primary endpoints are superiority to placebo on the WOMAC pain subscale, the WOMAC function subscale and patients' overall rating of disease status at 13 weeks. Non-inferiority to naproxen on the three scores is a secondary endpoint. Data are expected in the fourth quarter. ...